Situations of MTC in clients handled with liraglutide, another GLP-one receptor agonist, have already been claimed while in the postmarketing interval; the data in these studies are inadequate to establish or exclude a causal partnership in between MTC and GLP-one receptor agonist use in humans. Simply because medical trials are carried out belo